# Shanghai Bocimed Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-bocimed-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.bocimed.com
- Total disclosed funding: $15M
- Latest round: Series B (Sep 30, 2020)
- Investors on record: 4

## About

Based in Shanghai, China, and established in 2012, Shanghai Bocimed Pharmaceutical Co., Ltd. is a pharmaceutical company that focuses on drug delivery technology. It has two major centres in Shanghai Zhangjiang and Shanghai Lingang, a clinical subsidiary in Chengdu, and three R&D centres. It passed ISO9001:2015, and applied for more than 150 patents, including 42 authorized invention patents and 11 utility model patents. In 2014, its first clinical approval and first production approval were obtained. In 2016, it acquired the clinical contract research organization (CRO), Chengdu Runze Pharmaceutical Technology Development Co., Ltd. In 2020, it built the Shanghai Lingang R&D center and pilot-scale base. In 2022, it established a postdoctoral mobile workstation.

Shanghai Bocimed Pharmaceutical Co., Ltd. provides R&D, and production services for drug delivery preparations, including complex pharmaceutical preparations, solubilization pharmaceutical preparations, high-delivery drug preparation, and living biological technology. The complex pharmaceutical preparations include slow controlled release preparations, double layers, and long-acting injections. The solubilization pharmaceutical preparations include oral preparations, patches, and nasal sprays. It also provides drug intermediates customized manufacturing, and active pharmaceutical ingredient (API) customized manufacturing services. Its API can be categorized as tumor and immunogenic API, central nerve systems API, antiviral and anti-infective API, and metabolic and digestive API. Shanghai Bocimed Pharmaceutical Co., Ltd. will use the finances raised in February 2023 to perform clinical research and development, and industrial of new drugs, including BCM335, BCM331, BCM291, BCM332, BCM345, and BCM347.

## Funding rounds

- Series B, Sep 30, 2020, $15M — V.Stone Capital, Xingfu Capital, Changjiang Securities
- Series A, Feb 15, 2019 — Shanghai STVC Group, Xingfu Capital

## Investors

- Shanghai STVC Group (https://capitalatlas.ai/funds/shanghai-stvc-group) — Series A
- Xingfu Capital — Series A, Series B
- V.Stone Capital (https://capitalatlas.ai/funds/v-stone-capital) — Series B
- Changjiang Securities — Series B